Tercica

Tercica, Inc. was a biopharmaceutical company headquartered in Brisbane, California, whose principal focus was the development and commercialization of Increlex, a recombinant form of human insulin-like growth factor-1, or IGF-1. The company operated in a specialized segment of endocrinology rather than as a broad pharmaceutical manufacturer. Its work centered on children whose growth failure was associated with severe primary IGF-1 deficiency and on a narrower population of children with growth-hormone gene deletion who had developed neutralizing antibodies against growth hormone. Tercica did not originate the underlying molecule independently. It licensed rights from Genentech to develop, manufacture, and market Increlex, also identified as mecasermin or recombinant human IGF-1. The licensing arrangement gave Tercica responsibility for advancing the product through clinical development and regulatory review while relying on an established biotechnology partner for the origin of the technology and product rights. Increlex entered Phase III evaluation to assess safety and efficacy in children with primary IGF-1 deficiency, a rare condition characterized by inadequate growth despite the presence of growth hormone. The company’s regulatory strategy was built around obtaining approval for long-term treatment of growth failure in children with severe primary IGF-1 deficiency. It also sought recognition of a use in children with growth-hormone gene deletion who could no longer benefit from growth hormone because of neutralizing antibodies. This positioned Tercica in a narrow orphan or specialty-biopharmaceutical market in which clinical evidence, regulatory designation, manufacturing reliability, and access to pediatric endocrinology specialists were central to commercialization. Tercica also became involved in intellectual-property litigation concerning competing growth-related therapies. In 2007, a jury found that Insmed had infringed patents licensed to Tercica for Increlex. The resulting settlement required Insmed to stop selling Iplex in the United States for growth-deficiency treatment and to withdraw a European application seeking approval for that use. The dispute helped protect the commercial and regulatory position of Tercica’s licensed product, although it also underscored the competitive and patent-sensitive nature of the growth-factor market. In 2008, the Ipsen Group acquired Tercica. Following the acquisition, Tercica was renamed Ipsen Biopharmaceuticals, Inc., bringing the company and its product activities into Ipsen’s broader specialty-pharmaceutical organization. As a result, Tercica no longer operated as an independent corporate identity. Its historical significance rests primarily on the development and commercialization effort surrounding Increlex, the company’s specialized pediatric endocrinology focus, and the patent dispute that shaped competition around IGF-1-based treatment.

Tercica, Inc. was a California-based biopharmaceutical company established around the development of a highly specialized pediatric endocrinology product. Its main asset was Increlex, the brand name for mecasermin, a recombinant form of human insulin-like growth factor-1. The product was also described as recombinant human IGF-1, or rhIGF-1. Tercica licensed rights from Genentech to develop, manufacture, and market the therapy, making the company a commercial and clinical-development vehicle for a product originating from Genentech’s biotechnology work. The therapeutic rationale for Increlex was to address growth failure in children with severe primary IGF-1 deficiency. In this condition, the body does not produce or respond adequately to IGF-1 even though growth hormone may be present. Tercica also pursued a potential use in children with growth-hormone gene deletion who had developed neutralizing antibodies against growth hormone. These indications placed the company in a narrow, specialist market requiring long-term pediatric treatment and close supervision by endocrinologists. Tercica advanced Increlex into Phase III clinical trials designed to examine its safety and efficacy in children with primary IGF-1 deficiency. The company subsequently applied to the United States Food and Drug Administration for approval as a long-term treatment for growth failure in children with severe primary IGF-1 deficiency. Its strategy depended on demonstrating clinical benefit in a rare-disease population while establishing a viable manufacturing and commercialization platform for a recombinant biologic. The company’s development program was accompanied by a significant patent conflict. In 2007, Tercica pursued a case against Insmed concerning patents licensed for Increlex. A jury found that Insmed had infringed those patents. The parties then reached a settlement under which Insmed agreed to discontinue sales of Iplex in the United States for growth-deficiency treatment and to withdraw an application seeking European approval for that indication. The resolution limited a competing product’s presence in the relevant market and reinforced the importance of licensed intellectual property to Tercica’s business model. In 2008, Ipsen Group acquired Tercica. Ipsen subsequently changed the company’s name to Ipsen Biopharmaceuticals, Inc. This transaction integrated Tercica’s operations and product interests into Ipsen and ended Tercica’s independent corporate history. Accordingly, Tercica is best understood as a former specialty biopharmaceutical company whose identity was closely associated with Increlex, pediatric growth disorders, licensed biotechnology, and a patent dispute over competing IGF-1-related treatments.

• 2008

  Acquisition by Ipsen

  [1]Tercicaen.wikipedia.org

  Ipsen Group acquired Tercica and renamed it Ipsen Biopharmaceuticals, Inc.

• 2007

  Patent dispute with Insmed reaches settlement

  [1]Tercicaen.wikipedia.org

  A jury found that Insmed infringed patents licensed to Tercica for Increlex. The settlement required Insmed to stop selling Iplex in the United States for growth-deficiency treatment and to withdraw a European application for the same use.

A specialty biopharmaceutical company focused on pediatric endocrinology and growth failure associated with severe primary IGF-1 deficiency.

• Recombinant growth-factor therapy

  Increlex

  Increlex was Tercica’s principal product and the company’s central development and commercialization asset. It is mecasermin, a recombinant form of human insulin-like growth factor-1, also called rhIGF-1. Tercica pursued the product as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency and investigated its relevance to children with growth-hormone gene deletion who developed neutralizing antibodies to growth hormone. Tercica licensed the rights to develop, manufacture, and market Increlex from Genentech.

• 2008

  Acquisition and corporate renaming by IpsenM&A

  Background

  Ipsen Group acquired Tercica as part of its expansion of specialty-biopharmaceutical activities.

  Action taken

  Ipsen changed Tercica’s name to Ipsen Biopharmaceuticals, Inc.

  Aftermath

  Tercica ceased to operate as an independent corporate brand and became part of Ipsen’s organization.

  Source

• 2007

  Settlement of Increlex patent litigationOther

  Background

  Tercica brought a patent dispute against Insmed concerning intellectual property licensed for Increlex. A jury found that Insmed had infringed the relevant patents.

  Action taken

  Under the settlement, Insmed agreed to stop selling Iplex in the United States for growth-deficiency treatment and to withdraw a European application seeking approval for that use.

  Aftermath

  The settlement restricted a competing product’s use in the relevant market and protected Tercica’s licensed intellectual-property position.

  • Insmed — Insmed agreed to discontinue the specified United States sales and withdraw its related European application.

  Source

• 2008

  Ipsen acquires Tercica and renames the company[1]Tercicaen.wikipedia.org

  M&A · Leadership change

  Ipsen Group acquired Tercica and changed its corporate name to Ipsen Biopharmaceuticals, Inc., ending Tercica’s existence as an independent company.

• 2007

  Jury finds Insmed infringed patents licensed to Tercica[1]Tercicaen.wikipedia.org

  Lawsuit

  A patent dispute involving Tercica and Insmed concluded with a jury finding that Insmed infringed patents licensed to Tercica for Increlex. The subsequent settlement required Insmed to stop selling Iplex in the United States for growth-deficiency treatment and to withdraw a related European approval application.

1. 1Tercicaen.wikipedia.org